AxelOng
2021-11-05
Amazing
Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":846473141,"tweetId":"846473141","gmtCreate":1636109696511,"gmtModify":1636110384502,"author":{"id":4089463306606890,"idStr":"4089463306606890","authorId":4089463306606890,"authorIdStr":"4089463306606890","name":"AxelOng","avatar":"https://static.tigerbbs.com/8eaa7b50259b0329b74e09bc501ecd38","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Amazing </p></body></html>","htmlText":"<html><head></head><body><p>Amazing </p></body></html>","text":"Amazing","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/846473141","repostId":1168526565,"repostType":4,"repost":{"id":"1168526565","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636109309,"share":"https://www.laohu8.com/m/news/1168526565?lang=zh_CN&edition=full","pubTime":"2021-11-05 18:48","market":"us","language":"en","title":"Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168526565","media":"Tiger Newspress","summary":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug wa","content":"<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its shares rose over 9% in premarket trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer rose over 9% in premarket trading as its antiviral pill cut risk of severe COVID-19 by 89%<blockquote>辉瑞(Pfizer)在盘前交易中上涨超过9%，其抗病毒药物将严重COVID-19的风险降低了89%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-05 18:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.</p><p><blockquote>辉瑞公司周五表示，该公司针对COVID-19的实验性抗病毒药物的试验提前停止，此前该药物被证明可以将有严重疾病风险的成年人住院或死亡的几率降低89%。</blockquote></p><p> The results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.</p><p><blockquote>这一结果似乎超过了默克公司(Merck&Co Inc.)的药物molnupiravir的结果，该药物上个月被证明可以将同样具有严重疾病高风险的COVID-19患者死亡或住院的可能性减半。</blockquote></p><p> Full trial data is not yet available from either company.</p><p><blockquote>两家公司都尚未提供完整的试验数据。</blockquote></p><p> Pfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.</p><p><blockquote>辉瑞表示，计划向美国提交其药物的中期试验结果，该药物与一种名为利托那韦的旧抗病毒药物联合使用。食品和药物管理局作为其10月份开放的紧急使用申请的一部分。</blockquote></p><p> The combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.</p><p><blockquote>这种联合治疗的品牌名称为Paxlovid，包括每天两次服用三粒药丸。</blockquote></p><p> The planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.</p><p><blockquote>辉瑞研究中计划对1,219名患者进行分析，研究了被诊断患有轻度至中度COVID-19且至少有一种发展为严重疾病的风险因素（如肥胖或年龄较大）的人的住院或死亡情况。</blockquote></p><p> It found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.</p><p><blockquote>研究发现，在症状出现后三天内服用辉瑞药物的患者中，有0.8%住院治疗，没有人在治疗后28天内死亡。相比之下，安慰剂患者的住院率为7%。安慰剂组也有7例死亡。</blockquote></p><p> Rates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.</p><p><blockquote>在出现症状5天内接受治疗的患者的比率相似——治疗组1%住院，而安慰剂组为6.7%，其中包括10例死亡。</blockquote></p><p> Antivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.</p><p><blockquote>为了最有效，需要在感染发生之前尽早给予抗病毒药物。默克公司在症状出现后五天内测试了其药物。</blockquote></p><p> \"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.</p><p><blockquote>“我们发现我们确实具有很高的疗效，即使是在患者接受治疗五天后……人们可能会等待几天才能进行测试或其他事情，这意味着我们有时间治疗人们并从公共卫生的角度来看确实提供了好处，”辉瑞项目负责人安娜莉莎·安德森告诉路透社。</blockquote></p><p> The company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.</p><p><blockquote>该公司没有详细说明治疗的副作用，但表示约20%的治疗和安慰剂患者发生了不良事件。</blockquote></p><p> \"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.</p><p><blockquote>辉瑞首席执行官Albert Bourla表示：“这些数据表明，我们的口服抗病毒候选药物如果获得监管机构的批准，有可能挽救患者的生命，降低COVID-19感染的严重程度，并消除多达十分之九的住院治疗。”在一份声明中说。</blockquote></p><p> Infectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.</p><p><blockquote>传染病专家强调，通过广泛使用疫苗来预防新冠肺炎仍然是控制疫情的最佳方式，但只有58%的美国人完全接种了疫苗，世界许多地区的疫苗接种有限。</blockquote></p><p> Pfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.</p><p><blockquote>辉瑞的药物是蛋白酶抑制剂类药物的一部分，旨在阻断冠状病毒繁殖所需的酶。</blockquote></p><p> Merck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.</p><p><blockquote>默克公司的molnupiravir具有不同的作用机制，旨在将错误引入病毒的遗传密码。默克公司已向美国、英国和其他国家出售了数百万个疗程的治疗药物，该药物本周获得了英国监管机构的批准。</blockquote></p><p> Britain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.</p><p><blockquote>英国本月早些时候表示，已获得25万个疗程的辉瑞抗病毒药物。</blockquote></p><p> Pfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.</p><p><blockquote>辉瑞还在研究其药物是否可以被没有严重新冠肺炎风险因素的人使用，以及预防接触该病毒的人感染冠状病毒。</blockquote></p><p> Its shares rose over 9% in premarket trading.<img src=\"https://static.tigerbbs.com/190a24394aa60d689cf29552569f5e20\" tg-width=\"774\" tg-height=\"567\" width=\"100%\" height=\"auto\"></p><p><blockquote>其股价在盘前交易中上涨超过9%。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168526565","content_text":"A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.\nThe results appear to surpass those seen with Merck & Co Inc's pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high risk of serious illness.\nFull trial data is not yet available from either company.\nPfizer said it plans to submit interim trial results for its pill, which is given in combination with an older antiviral called ritonavir, to the U.S. Food and Drug Administration as part of the emergency use application it opened in October.\nThe combination treatment, which will have the brand name Paxlovid, consists of three pills given twice daily.\nThe planned analysis of 1,219 patients in Pfizer's study looked at hospitalizations or deaths among people diagnosed with mild to moderate COVID-19 with at least one risk factor for developing severe disease, such as obesity or older age.\nIt found that 0.8% of those given Pfizer's drug within three days of symptom onset were hospitalized and none had died by 28 days after treatment. That compared with a hospitalization rate of 7% for placebo patients. There were also seven deaths in the placebo group.\nRates were similar for patients treated within five days of symptoms - 1% of the treatment group was hospitalized, compared with 6.7% for the placebo group, which included 10 deaths.\nAntivirals need to be given as early as possible, before an infection takes hold, in order to be most effective. Merck tested its drug within five days of symptom onset.\n\"We saw that we did have high efficacy, even if it was five days after a patient has been treated ... people might wait a couple of days before getting a test or something, and this means that we have time to treat people and really provide a benefit from a public health perspective,\" Annaliesa Anderson, head of the Pfizer program, told Reuters.\nThe company did not detail side effects of the treatment, but said adverse events happened in about 20% of both treatment and placebo patients.\n\"These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer Chief Executive Albert Bourla said in a statement.\nInfectious disease experts stress that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic, but only 58% of Americans are fully vaccinated and access in many parts of the world is limited.\nPfizer's drug, part of a class known as protease inhibitors, is designed to block an enzyme the coronavirus needs in order to multiply.\nMerck's molnupiravir has a different mechanism of action designed to introduce errors into the genetic code of the virus. Merck has already sold millions of courses of the treatment, which was approved this week by U.K. regulators, to the United States, the U.K. and others.\nBritain said earlier this month it had secured 250,000 courses of Pfizer's antiviral.\nPfizer is also studying whether its pill could be used by people without risk factors for serious COVID-19 as well as to prevent coronavirus infection in people exposed to the virus.\nIts shares rose over 9% in premarket trading.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":791,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/846473141"}
精彩评论